Assessment of Minimal Residual Disease in Standard-Risk AML

Authors:

Abstract
To the Editor: Ivey and colleagues (Feb. 4 issue)1 tested the prognostic value of the presence of a mutation in the gene encoding nucleophosmin (NPM1) in patients with acute myeloid leukemia (AML) who were in complete hematologic remission after a second cycle of chemotherapy,2 although the recovery of cell counts in peripheral blood was not required for a determination of such remission. Some of the patients were in remission after the first cycle of chemotherapy and some were not. Moreover, some of the patients in remission had normal blood counts and some did not. Other studies have shown . . .

This publication has 38 references indexed in Scilit: